Skip to main content
CTIS.
EU
Conditions
IMPs
Countries
Sponsors
Sites
Trial Map
Safety
Transparency
Landscape
EN — English
BG — Български
CS — Čeština
DA — Dansk
DE — Deutsch
EL — Ελληνικά
ES — Español
ET — Eesti
FI — Suomi
FR — Français
GA — Gaeilge
HR — Hrvatski
HU — Magyar
IT — Italiano
LT — Lietuvių
LV — Latviešu
MT — Malti
NL — Nederlands
PL — Polski
PT — Português
RO — Română
SK — Slovenčina
SL — Slovenščina
SV — Svenska
NO — Norsk
CTIS.
EU
✕
Conditions
IMPs
Countries
Sponsors
Sites
Trial Map
Safety
Transparency
Landscape
Notice
This is an independent non-profit initiative. We are not affiliated with the European Medicines Agency (EMA) or the official CTIS system. For the official EU Clinical Trials Information System, visit:
EMA Registry →
CTIS.eu
›
Conditions
› non-Hodgkin Lymphomas Subtypes: DLBCL - ORPHA: 544 Agressive B-cell non-Hodgkin lymphoma ORPHA: 300846 High grade B-cell lymphoma with MYCand/or BCL2 and/or BCL6 rearrangement ORPHA: 480541
non-Hodgkin Lymphomas Subtypes: DLBCL - ORPHA: 544 Agressive B-cell non-Hodgkin lymphoma ORPHA: 300846 High grade B-cell lymphoma with MYCand/or BCL2 and/or BCL6 rearrangement ORPHA: 480541
1 total trials
1 recruiting
Filter these 1 trials by phase, country, sponsor and more.
Open in Search →
Phase I, Open-label, Single-center, Dose Escalation Study to Assess Safety and Tolerability of anti-CD19 CAR-T Cells in Patients with B-cell …
Recruiting
2024-519318-30-00
1
2025-06-25
Showing 1–1 of 1 trials